Table 2.
Univariate analysis between clinical characteristics and pCR.
| Variable | Total (n=221) | pCR (n=53) | OR | CI (95%) | P |
|---|---|---|---|---|---|
| Age(years) | |||||
| ≤49 | 115 (52.0%) | 30 (56.6%) | Ref. | Ref. | Ref. |
| >49 | 106 (48.0%) | 23 (43.4%) | 0.785 | 0.422-1.462 | 0.446 |
| Menopause | |||||
| No | 128 (57.9%) | 35 (66.0%) | Ref. | Ref. | Ref. |
| Yes | 93 (42.1%) | 18 (34.0%) | 0.638 | 0.335-1.215 | 0.171 |
| Number of births | |||||
| 0 | 27 (12.2%) | 7 (13.2%) | Ref. | Ref. | Ref. |
| 1 | 137 (62.0%) | 34 (64.1%) | 0.943 | 0.367-2.424 | 0.903 |
| 2 | 44 (19.9%) | 9 (17.0%) | 0.735 | 0.237-2.275 | 0.593 |
| >2 | 13 (5.9%) | 3 (5.7%) | 0.857 | 0.182-4.042 | 0.846 |
| T Stage | |||||
| cT1+cT2 | 174 (78.7%) | 46 (86.8%) | Ref. | Ref. | Ref. |
| cT3+cT4 | 47 (21.3%) | 7 (13.2%) | 0.487 | 0.204-1.163 | 0.105 |
| N Stage | |||||
| N0 | 11 (5.0%) | 2 (3.8%) | Ref. | Ref. | Ref. |
| N1+N2+N3 | 210 (95.0%) | 51 (96.2%) | 1.443 | 0.302-6.898 | 0.646 |
| Hormone receptors | |||||
| ER+/PR+ | 90 (40.7%) | 11 (20.8%) | Ref. | Ref. | Ref. |
| ER+/PR- | 31 (14.0%) | 5 (9.4%) | 1.381 | 0.439-4.346 | 0.581 |
| ER-/PR- | 94 (42.5%) | 37 (69.8%) | 4.662 | 2.193-9.912 | <0.001 |
| HER2 | |||||
| Negative | 142 (64.3%) | 25 (47.2%) | Ref. | Ref. | Ref. |
| Positive | 79 (35.7%) | 28 (52.8%) | 2.569 | 1.366-4.832 | 0.003 |
| Ki67(%) | |||||
| ≤14 | 58 (26.2%) | 7 (13.2%) | Ref. | Ref. | Ref. |
| >14 | 163 (73.8%) | 46 (86.8%) | 2.864 | 1.212-6.773 | 0.017 |
| p53 | |||||
| Negative | 130 (58.8%) | 32 (60.4%) | Ref. | Ref. | Ref. |
| Positive | 91 (41.2%) | 21 (39.6%) | 0.919 | 0.489-1.725 | 0.792 |
| MetS status | |||||
| No | 172 (77.8%) | 48 (90.6%) | Ref. | Ref. | Ref. |
| Yes | 49 (22.2%) | 5 (9.4%) | 0.294 | 0.110-0.785 | 0.015 |
pCR, pathologic complete response; OR, odds ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; MetS, metabolic syndrome.